A randomized, double-blind, single dose phase 1 study assessing safety and PK of GSK2878175
Latest Information Update: 25 Aug 2021
At a glance
- Drugs GSK 2878175 (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Pharmacokinetics
Most Recent Events
- 25 Aug 2021 New trial record